Drug Approval | August 19, 2022
Lupin receives approval from U.S. FDA for Rufinamide Tablets USP
The product will be manufactured at Lupin's facility in Goa, India.
The product will be manufactured at Lupin's facility in Goa, India.
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
Collaboration supports multiple discovery efforts, including vaccines
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Company appoints five new independent directors to reconstituted board
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The product will be manufactured at Lupin’s facility in Goa, India.
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Subscribe To Our Newsletter & Stay Updated
